Serologic antiglycan antibodies in inflammatory bowel disease.
about
Emerging role of novel biomarkers in the diagnosis of inflammatory bowel diseaseLaboratory markers in ulcerative colitis: Current insights and future advancesDifferential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectivesBiomarkers of inflammatory bowel disease.Serum anti-glycan antibodies in paediatric-onset Crohn's disease: association with disease phenotype and diagnostic accuracy.Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.Biomarkers in inflammatory bowel disease: current practices and recent advances.The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.Crohn's disease complicated by strictures: a systematic review.Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysisThe role of autoantibodies in inflammatory bowel disease.Recommendations for identifying Crohn's disease patients with poor prognosis.Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression?Personalizing therapy for inflammatory bowel diseases.Towards personalized care in IBD.Overcoming difficulty in diagnosis and differential diagnosis of Crohn's disease: the potential role of serological and genetic tests.Inflammatory Bowel Disease-Unclassified in Children: Diagnosis and Pharmacological Management.Bowel Thickening in Crohn's Disease: Fibrosis or Inflammation? Diagnostic Ultrasound Imaging Tools.Serologic antibodies in relation to outcome in postoperative Crohn's disease.Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment.Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections
P2860
Q26768273-180648F3-6A67-4074-BE09-B5246AC710FEQ27027022-D5201530-45C9-444B-B671-7FC0AFCF0359Q28085134-D29DA255-4FC4-4BEC-8A2D-56E32029105EQ33746983-3E7C581F-1707-4D77-BC46-49D1C20B78DEQ34258150-A00D3762-FF86-4509-818E-B796317BFA73Q34367414-27E2B735-3B76-41D3-8447-A3FBE4F0B1A3Q35716279-3B4D9552-DECB-4953-A4B5-8E3B2A4C7818Q35840853-2E82F3E6-0C24-4A91-8853-9841B79CB5FDQ36898669-0FEE8152-5566-45C1-A218-CF9E32A91255Q36945422-A898F161-251F-47B4-911E-B360B6553C25Q37980405-BD8E798F-DBDD-4601-8337-9DE7ED116CB1Q38020711-79BA2DD3-9780-4DAA-906E-1C7FB37929CCQ38068962-F57295F3-91F2-404F-B3C6-827B0A2C3CF6Q38072225-0EA7EE50-FD4C-4778-818B-55534064D6D6Q38132279-6534E85C-6528-4752-9ABE-3B1DDA9C4314Q38171924-2213F844-4EFD-4A87-9E8E-DC8692A86AAEQ38570962-E57BFC6E-1208-4D6F-95A9-AD1D88B73A8EQ38985144-60EFEE68-9966-41FE-9BBE-9C8D9386DB9EQ39046622-0B40A743-A709-4D04-9088-7A3FAE78AEFDQ40409129-E2500D5C-F992-4A4B-99E7-5762E8694539Q45898977-DEA23886-A14B-4117-8556-AE97F8E41160Q52723572-DE598311-0668-4758-9FE4-87235F31341FQ57089314-34FA1C82-7A43-4AC4-AE2A-82ED9CAE7F80
P2860
Serologic antiglycan antibodies in inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serologic antiglycan antibodies in inflammatory bowel disease.
@en
Serologic antiglycan antibodies in inflammatory bowel disease.
@nl
type
label
Serologic antiglycan antibodies in inflammatory bowel disease.
@en
Serologic antiglycan antibodies in inflammatory bowel disease.
@nl
prefLabel
Serologic antiglycan antibodies in inflammatory bowel disease.
@en
Serologic antiglycan antibodies in inflammatory bowel disease.
@nl
P2860
P921
P356
P1476
Serologic antiglycan antibodies in inflammatory bowel disease
@en
P2093
Florian Rieder
Maria Papp
P2860
P304
P356
10.1038/AJG.2010.505
P407
P577
2011-01-18T00:00:00Z